Loading...

PE/Cyanine7 anti-mouse CD62L Antibody

Pricing & Availability
Clone
MEL-14 (See other available formats)
Regulatory Status
RUO
Other Names
L-selectin, LECAM-1, Ly-22, LAM-1, MEL-14
Isotype
Rat IgG2a, κ
Ave. Rating
Submit a Review
Product Citations
publications
MEL-14_PECy7_090707
C57BL/6 mouse splenocytes were stained with CD62L (clone MEL-14) PE/Cyanine7 (filled histogram) or rat IgG2a PE/Cyanine7 isotype control (open histogram).
  • MEL-14_PECy7_090707
    C57BL/6 mouse splenocytes were stained with CD62L (clone MEL-14) PE/Cyanine7 (filled histogram) or rat IgG2a PE/Cyanine7 isotype control (open histogram).
Compare all formats See PE/Cyanine7 spectral data
Cat # Size Price Quantity Check Availability Save
104417 25 µg $88
Check Availability


Need larger quantities of this item?
Request Bulk Quote
104418 100 µg $215
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD62L is a 74-95 kD glycoprotein also known as L-selectin, LECAM-1, Ly-22, LAM-1, and MEL-14. It is a member of the selectin family and is expressed on the majority of B and naïve T cells, a subset of memory T cells, monocytes, granulocytes, most thymocytes, and a subset of NK cells. CD62L is important in lymphocyte homing to high endothelial venules (HEV) in peripheral lymph nodes and leukocyte "rolling" on activated endothelium. CD62L also contributes to neutrophil emigration at inflammatory sites. CD62L is rapidly shed from lymphocytes and neutrophils upon cellular activation and the expression levels of CD62L (in conjunction with other markers) have been used to distinguish naïve, effector, and memory T cells. CD62L has been reported to interact with CD34, GlyCAM-1, and MAdCAM-1.

Product Details
Technical data sheet

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Rat
Immunogen
C3H/eb mouse B lymphoma 38C-13
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography, and conjugated with PE/Cyanine7 under optimal conditions.
Concentration
0.2 mg/ml
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤ 0.25 µg per 106 cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

Excitation Laser
Blue Laser (488 nm)
Green Laser (532 nm)/Yellow-Green Laser (561 nm)
Application Notes

Additional reported applications (for the relevant formats) include: immunoprecipitation1-3, complement-dependent cytotoxicity4, in vivo and in vitro blocking of adhesion1-3,5, and immunohistochemical staining of acetone-fixed frozen sections and zinc-fixed paraffin-embedded sections6. The Ultra-LEAF™ purified antibody (Endotoxin < 0.01 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. Nos. 104457-104462).

Additional Product Notes
BioLegend is in the process of converting the name PE/Cy7 to PE/Cyanine7. The dye molecule remains the same, so you should expect the same quality and performance from our PE/Cyanine7 products. Please contact Technical Service if you have any questions.
Application References

(PubMed link indicates BioLegend citation)
  1. Gallatin WM, et al. 1983. Nature 304:30. (IP, Block)
  2. Siegelman MH, et al. 1990. Cell 61:611. (IP, Block)
  3. Lewinsohn DM, et al. 1987. J. Immunol. 138:4313. (IP, Block)
  4. Iwabuchi K, et al. 1991. Immunobiology 182:161. (CMCD)
  5. Pizcueta P, et al. 1994. Am. J. Pathol. 145:461.
  6. Reichert RA, et al. 1986. J. Immunol. 136:3535. (IHC, FC)
  7. Olver S, et al. 2006. Cancer Res. 66:571.
  8. Fukushima A, et al. 2006. Invest. Ophthalmol. Vis. Sci. 47:657. PubMed
  9. Benson MJ, et al. 2007. J. Exp. Med. doi:10.1084/jem.20070719. (FC) PubMed
  10. Chappaz S, et al. 2007. Blood doi:10.1182/blood-2007-02-074245. (FC) PubMed
  11. Lee JW, et al. 2006. Nature Immunol. 8:181.
  12. Shigeta A, et al. 2008. Blood 112:4915 (FC) PubMed
  13. de Vries VC, et al. 2009. Am. J. Transplant. 9:2270 PubMed
Product Citations
  1. Oh–Hora M, et al. 2019. J Immunol. 202:2616. PubMed
  2. Komuczki J, et al. 2019. Immunity. 50:1289. PubMed
  3. Gordan S, et al. 2020. Cell Reports. 29(10):3033-3046.e4.. PubMed
  4. Ye ZW, et al. 2022. Cell Mol Immunol. 19:588. PubMed
  5. Bruggemann TR, et al. 2022. iScience. 25:105185. PubMed
  6. Bhatt K, et al. 2018. mSphere. 3:e00352. PubMed
  7. Li X, et al. 2022. Nat Commun. 13:2794. PubMed
  8. Gerber AN, et al. 2021. Cell Rep. 37:109816. PubMed
  9. Uzhachenko RV, et al. 2021. Cell Reports. 35(1):108944. PubMed
  10. Gupta SS, et al. 2019. Cell Rep. 29:1862. PubMed
  11. Fernandes RA, et al. 2020. eLife. 9:e58463.. PubMed
  12. Ibrahim M, et al. 2016. J Evid Based Complementary Altern Med. 21: 171 - 176. PubMed
  13. Huang W, et al. 2014. J Immunol. 193:2267. PubMed
  14. Wu J, et al. 2020. Cell Reports. 31(1):107484. PubMed
  15. Kinder JM, et al. 2020. Cell Reports. 31(12):107784.. PubMed
  16. Nguyen T, et al. 2017. Clin Transl Immunology. 10.1038/cti.2017.4. PubMed
  17. He C, et al. 2020. Clin Transl Med. 10:e39. PubMed
  18. Nagai Y, et al. 2019. Front Immunol. 10:174. PubMed
  19. LaFleur MW, et al. 2019. Nat Immunol. 20:1335. PubMed
  20. Wu J, et al. 2020. Sci Adv. 6:eaba3458. PubMed
  21. Tu X, et al. 2022. Nat Commun. 13:6977. PubMed
  22. Li B, et al. 2015. Sci Rep. 5: 14793. PubMed
  23. Hirose M, et al. 2011. Biochem Biophys Res Commun. 414:437. PubMed
  24. Zhang H, et al. 2020. Cancer Cell. 37(1):37-54.e9.. PubMed
  25. Gordon RA, et al. 2020. PLoS One. 15:e0226396. PubMed
  26. Geiger R, et al. 2016. Cell. 167:829-842. PubMed
  27. Cheng K, et al. 2021. Nat Commun. 12:2041. PubMed
  28. Len-Letelier RA, et al. 2020. Frontiers in Immunology. 11:583382. PubMed
  29. Snell LM, et al. 2018. Immunity. 49:678. PubMed
  30. He X, et al. 2021. Small. 17:e2007165. PubMed
  31. He X, et al. 2021. Adv Sci (Weinh). 8:e2103023. PubMed
  32. Canton J, et al. 2021. Nat Immunol. 22:140. PubMed
  33. Kim C, et al. 2019. Cell Rep. 29:2202. PubMed
  34. Ringel AE, et al. 2020. Cell. 183(7):1848-1866.e26. PubMed
  35. Barsoumian HB, et al. 2020. J Immunother Cancer. 8:00. PubMed
  36. Burrack K, et al. 2015. J Immunol. 194:678. PubMed
  37. Stenström M, et al. 2010. Int Immunopharmacol. 10:837. PubMed
  38. Jing Y, et al. 2020. Sci Adv. 6:eaax9455. PubMed
  39. Place D, et al. 2017. PLoS One. 10.1371/journal.pone.0190384. PubMed
  40. Hu Y, et al. 2022. J Nanobiotechnology. 20:417. PubMed
  41. Zhao X, et al. 2022. Nat Protoc. 17:2240. PubMed
  42. He X, et al. 2022. Cancer Immunol Res. 10:314. PubMed
  43. DiPiazza AT, et al. 2021. Immunity. 54(8):1869-1882.e6. PubMed
  44. LaFleur MW, et al. 2019. Nat Commun. 10:1668. PubMed
  45. Masiuk KE, et al. 2019. Cell Stem Cell. 24:309. PubMed
  46. Horkova V, et al. 2020. Cell Reports. 30(5):1504-1514.e7.. PubMed
  47. Dey S, et al. 2020. J Immunother Cancer. 8:. PubMed
  48. Corbett KS, et al. 2020. Nature. 586:567. PubMed
  49. Morris AB, et al. 2020. Immunity. 52(1):136-150.e6.. PubMed
  50. Pham D, et al. 2019. Cell Rep. 29:1203. PubMed
  51. Yu X, et al. 2019. Nat Commun. 10:574. PubMed
  52. Li G, et al. 2021. Front Oncol. 11:734593. PubMed
  53. Robinett RA et al. 2018. Cell systems. 7(1):41-48 . PubMed
  54. Yang BH, et al. 2020. Cell Reports. 27(12):3629-3645.e6.. PubMed
  55. Kretschmer L, et al. 2020. Nat Commun. 0.536805556. PubMed
  56. Guo S, et al. 2021. Sci Rep. 11:23745. PubMed
  57. Severance AL, et al. 2022. iScience. 25:104400. PubMed
  58. Hamaidi I, et al. 2020. Cell Metabolism. 32(3):420-436.e12. PubMed
  59. Martina M, et al. 2016. J Am Soc Nephrol. 27: 1113-1123. PubMed
  60. Jiang L, et al. 2020. Cell. 183(5):1219-1233.e18. PubMed
  61. Motwani MP, et al. 2018. JCI Insight. 3:e94463. PubMed
  62. Niven J, et al. 2019. Cell Rep. 28:21. PubMed
  63. He X, et al. 2021. J Immunother Cancer. 9:. PubMed
  64. Danzer H, et al. 2020. Elife. 9:00. PubMed
  65. Xu W, et al. 2021. Immunity. 54(3):526-541.e7. PubMed
  66. Yoshida H, et al. 2019. Cell. 176:897. PubMed
  67. Werner A, et al. 2021. iScience. 24:103076. PubMed
  68. Li J, et al. 2021. Cell Rep. 37:110124. PubMed
  69. Kohn M, et al. 2021. Front Immunol. 626627:12. PubMed
  70. Xu C, et al. 2021. Cell Reports. 35(11):109235. PubMed
  71. Kitamoto S, et al. 2020. Cell. 182(2):447-462.e14. PubMed
  72. Charlton J, et al. 2015. PLoS One. 10:119200. PubMed
  73. Seeling M, et al. 2013. Proc Natl Acad Sci U S A. 110:10729. PubMed
  74. Angela M, et al. 2016. Nat Commun. 7:13683. PubMed
  75. Jaeger N, et al. 2020. Cell Rep. 33:108331. PubMed
  76. Gonzalez MM, et al. 2021. J Clin Invest. 131:. PubMed
  77. Hu Y, et al. 2021. J Nanobiotechnology. 19:416. PubMed
  78. Du Z, et al. 2020. J Allergy Clin Immunol. . PubMed
  79. Laczkó D, et al. 2020. Immunity. 53:724. PubMed
  80. BJ L, et al. 2017. J Exp Med . 10.1084/jem.20161461. PubMed
  81. Mohammed RN, et al. 2019. Sci Rep. 4.185416667. PubMed
  82. Li CY, et al. 2022. Int J Mol Sci. 23:. PubMed
RRID
AB_313102 (BioLegend Cat. No. 104417)
AB_313103 (BioLegend Cat. No. 104418)

Antigen Details

Structure
Selectin, 95 kD (neutrophils) or 74 kD (lymphocytes)
Distribution

Subsets of B and T cells, monocytes, granulocytes, subset of NK cells

Function
Lymphocyte homing to HEV, rolling on activated endothelium
Ligand/Receptor
CD34, GlyCAM-1, MAdCAM-1
Cell Type
B cells, Granulocytes, Monocytes, Neutrophils, NK cells, T cells, Tregs
Biology Area
Cell Adhesion, Cell Biology, Costimulatory Molecules, Immunology, Innate Immunity
Molecular Family
Adhesion Molecules, CD Molecules
Antigen References

1. Barclay AN, et al. 1997. The Leukocyte Antigen FactsBook Academic Press.
2. Kishimoto TK, et al. 1990. P. Natl. Acad. Sci. USA 87:2244.
3. Tedder TF, et al. 1995. J. Exp. Med. 181:2259.

Gene ID
20343 View all products for this Gene ID
UniProt
View information about CD62L on UniProt.org

Related FAQs

There are no FAQs for this product.
Go To Top Version: 1    Revision Date: 11/30/2012

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login/Register
Remember me
Forgot your password? Reset Password
Request an Account